Also found in: Dictionary.
Related to Sinemet: Sinemet cr


trademark for a combination of carbidopa and levodopa used in treatment of parkinsonism.


Apo-Levocarb (CA), Co-carledopa (UK), Dom-Levo-Carbidopa (CA), Half Sinemet (UK), Novo-Levocarbidopa (CA), Nu-Levocarb (CA), Sinemet, Sinemet CR, Tilolec (UK)

Pharmacologic class: Dopamine agonist

Therapeutic class: Antiparkinsonian

Pregnancy risk category C


After conversion to dopamine in CNS, levodopa acts as a neurotransmitter, relieving symptoms of Parkinson's disease. Carbidopa prevents destruction of levodopa, making more levodopa available to be decarboxylated to dopamine in brain.


Tablets: 10 mg carbidopa/100 mg levodopa, 25 mg carbidopa/100 mg levodopa, 25 mg carbidopa/250 mg levodopa

Tablets (extended-release): 25 mg carbidopa/100 mg levodopa, 50 mg carbidopa/200 mg levodopa

Indications and dosages

Idiopathic Parkinson's disease; parkinsonism; symptomatic parkinsonism

Conventional tablets-

Adults not currently receiving levodopa: Initially, 10 mg carbidopa/100 mg levodopa P.O. three to four times daily or 25 mg carbidopa/100 mg levodopa t.i.d.; may be increased q 1 to 2 days until desired effect occurs

Adults converting from levodopa alone (less than 1.5 g/day): Initially, 25 mg carbidopa/100 mg levodopa three to four times daily; may be increased q 1 to 2 days until desired effect occurs

Adults converting from levodopa alone (more than 1.5 g/day): Initially, 25 mg carbidopa/250 mg levodopa three to four times daily; may be increased q 1 to 2 days until desired effect occurs

Extended-release tablets-

Adults not currently receiving levodopa: Initially, 50 mg carbidopa/200 mg levodopa P.O. b.i.d., with doses spaced at least 6 hours apart

Adults converting from standard carbidopa-levodopa: Initiate therapy with at least 10% more levodopa content/day (may need up to 30% more) given at 4- to 8-hour intervals while awake; wait 3 days between dosage changes. Some patients may need higher dosages and shorter dosing intervals.


• Hypersensitivity to drug or tartrazine

• Angle-closure glaucoma

• MAO inhibitor use within past 14 days

• Malignant melanoma

• Breastfeeding


Use cautiously in:

• cerebrovascular, renal, hepatic, or endocrine disease

• history of cardiac, psychiatric, or ulcer disease

• abrupt drug discontinuation or dosage

• pregnant patients

• children ages 18 and under (safety not established).


• Give dose as close as possible to time ordered to ensure stable drug blood level.

• Know that giving extended-release form with food increases drug bioavailability.

• If patient needs general anesthesia, continue drug therapy as appropriate (if he's allowed to have oral fluids and drugs).

Be aware that drug shouldn't be withdrawn abruptly.

Adverse reactions

CNS: anxiety, dizziness, hallucinations, memory loss, headache, numbness, confusion, insomnia, nightmares, delusions, psychotic changes, depression, dementia, poor coordination, worsening hand tremor

CV: cardiac irregularities, palpitations, orthostatic hypotension

EENT: blurred vision, diplopia, mydriasis, eyelid twitching, difficulty swallowing

GI: nausea, vomiting, diarrhea, constipation, abdominal pain or discomfort, flatulence, excessive salivation, dry mouth, anorexia, upper GI hemorrhage (with history of peptic ulcer)

GU: urinary retention, urinary incontinence, dark urine

Hematologic: hemolytic anemia, leukopenia

Hepatic: hepatotoxicity

Musculoskeletal: muscle twitching, involuntary or spasmodic movements

Respiratory: hyperventilation

Skin: melanoma, flushing, rash, abnormally dark sweat

Other: altered or bitter taste, burning sensation of tongue, tooth grinding (especially at night), weight changes, hot flashes, hiccups


Drug-drug. Anticholinergics: decreased carbidopa-levodopa absorption

Antihypertensives: additive hypotension

Haloperidol, papaverine, phenothiazines, phenytoin, reserpine: reversal of carbidopa-levodopa effects

Inhalation hydrocarbon anesthetics: increased risk of arrhythmias

MAO inhibitors: hypertensive reactions

Methyldopa: altered efficacy of carbidopa-levodopa, increased risk of adverse CNS reactions

Pyridoxine: antagonism of carbidopa-levodopa effects

Selegiline: increased risk of adverse reactions

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, lactate dehydrogenase, low-density lipoproteins, protein-bound iodine, uric acid: increased levels
Coombs' test: false-positive result

Granulocytes, hemoglobin, platelets, white blood cells: decreased values

Urine glucose, urine ketones: test interference

Drug-food. Foods rich in pyridoxine (liver, yeast, cereals): reversal of carbidopa-levodopa effects

Drug-herbs. Kava: decreased carbidopa-levodopa efficacy

Octacosanol: worsening of dyskinesia

Drug-behaviors. Cocaine use: increased risk of adverse reactions to carbidopa-levodopa

Patient monitoring

• Monitor patient for orthostatic hypotension.

• Assess patient's need for drug "holiday" if his response to drug decreases.

Patient teaching

Inform patient that muscle and eyelid twitching may indicate toxicity. Tell him to report these symptoms immediately.

Caution patient not to stop taking drug abruptly.

• Instruct patient to swallow extended-release tablets whole without crushing or chewing them.

• Advise patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness caused by sudden blood pressure drop.

• Tell patient that drug may darken or discolor his urine and sweat.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.


A trademark for the drug combination of carbidopa and L-dopa.


a trademark for a fixed-combination drug containing a peripheral dopa decarboxylase inhibitor (carbidopa) and an antiparkinsonian (levodopa) that can enter the central nervous system.


Neurology An anti-parkinsonian containing levodopa, carbidopa


A brand name for LEVODOPA in combination with carbidopa.
References in periodicals archive ?
Strength and stretch physical therapy (PT) has demonstrated a decrease in falls and a slower progression of bradykinesia, while Sinemet and Amantidine only have short-lived benefit (4,6) and negatively augment the excessive daytime fatigue caused by the dysregulated sleep architecture.
6 December 2011 - US XenoPort Inc (NASDAQ:XNPT) unveiled on Monday preliminary top-line data from a Phase II, randomised, crossover study that compared optimised treatment with either Sinemet (immediate-release levodopa/carbidopa) or XP21279 co-formulated with carbidopa (279/CD) in advanced Parkinson's disease patients with motor fluctuations.
On the day of surgery, he took all his usual medications, including his midday dose of Sinemet one hour prior to surgery as requested.
this' Chemist and Druggist found more than 50 drugs out of stock at wholesalers, and some of the most difficult to obtain products include antidepressant Cipralex, breast cancer drug Femara, Sinemet for Parkinson's disease and Zyprexa for bipolar disorder.
Carbidopalevodopa is marketed under four brand names in the United States: Sinemet [R], Sinemet CR [R] (Sinemet controlled release), Parcopa [R] (an orally disintegrating tablet), and Stalevo [R] (a combination product of carbidopa-levodopa and entacapone) (PDE 2010c).
The Parkinson's drug Sinemet, breast cancer drug Femara, schizophrenia medicine Zyprexa and the antidepressant Cipralexare are among the most difficult to obtain.
The Parkinson's drug Sinemet, breast cancer drug Femara, schizophrenia medicine Zyprexa and the anti-depressant Cipralexare are among the most difficult to obtain.
Pharmacotherapy for restless legs syndrome in chronic kidney disease Drug Class (initial Advantages Disadvantages dose, maximum dose) Levodopa with carbidopa - effective for RLS - decreasing response (Sinemet[R], Sinemet without CKD with continual treatment CR[R]) (50-400 mg (i.
If the patient is on Sinemet (a combination of L-dopa and carbidopa), B6 may actually have a synergistic effect.
Recovery from vegetative state of six months' duration associated with Sinemet (levodopa/carbidopa).
These two agents combined in a carbidopa : levodopa ratio of 1:4 or 1:10 is known by the trade name Sinemet [R].